WO2003022752A9 - Biofilm reduction in crossflow filtration systems - Google Patents

Biofilm reduction in crossflow filtration systems

Info

Publication number
WO2003022752A9
WO2003022752A9 PCT/US2002/027612 US0227612W WO03022752A9 WO 2003022752 A9 WO2003022752 A9 WO 2003022752A9 US 0227612 W US0227612 W US 0227612W WO 03022752 A9 WO03022752 A9 WO 03022752A9
Authority
WO
WIPO (PCT)
Prior art keywords
mixture
ethoxylated
weight
concentration
surfactants
Prior art date
Application number
PCT/US2002/027612
Other languages
French (fr)
Other versions
WO2003022752A1 (en
Inventor
John W Baldridge
Andrew Michalow
Original Assignee
Advanced Biocatalytics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Biocatalytics Corp filed Critical Advanced Biocatalytics Corp
Priority to EP02757479A priority Critical patent/EP1423337A4/en
Publication of WO2003022752A1 publication Critical patent/WO2003022752A1/en
Publication of WO2003022752A9 publication Critical patent/WO2003022752A9/en

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D65/00Accessories or auxiliary operations, in general, for separation processes or apparatus using semi-permeable membranes
    • B01D65/02Membrane cleaning or sterilisation ; Membrane regeneration
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D61/00Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/02Reverse osmosis; Hyperfiltration ; Nanofiltration
    • B01D61/025Reverse osmosis; Hyperfiltration
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D61/00Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/02Reverse osmosis; Hyperfiltration ; Nanofiltration
    • B01D61/04Feed pretreatment
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D61/00Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14Ultrafiltration; Microfiltration
    • B01D61/16Feed pretreatment
    • CCHEMISTRY; METALLURGY
    • C02TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02FTREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F1/00Treatment of water, waste water, or sewage
    • C02F1/44Treatment of water, waste water, or sewage by dialysis, osmosis or reverse osmosis
    • C02F1/441Treatment of water, waste water, or sewage by dialysis, osmosis or reverse osmosis by reverse osmosis
    • CCHEMISTRY; METALLURGY
    • C02TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02FTREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F3/00Biological treatment of water, waste water, or sewage
    • C02F3/34Biological treatment of water, waste water, or sewage characterised by the microorganisms used
    • C02F3/342Biological treatment of water, waste water, or sewage characterised by the microorganisms used characterised by the enzymes used
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D2311/00Details relating to membrane separation process operations and control
    • B01D2311/04Specific process operations in the feed stream; Feed pretreatment
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D2321/00Details relating to membrane cleaning, regeneration, sterilization or to the prevention of fouling
    • B01D2321/16Use of chemical agents
    • B01D2321/166Use of enzymatic agents
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D2321/00Details relating to membrane cleaning, regeneration, sterilization or to the prevention of fouling
    • B01D2321/16Use of chemical agents
    • B01D2321/168Use of other chemical agents
    • CCHEMISTRY; METALLURGY
    • C02TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02FTREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F2209/00Controlling or monitoring parameters in water treatment
    • C02F2209/36Biological material, e.g. enzymes or ATP
    • CCHEMISTRY; METALLURGY
    • C02TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02FTREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F2305/00Use of specific compounds during water treatment
    • C02F2305/04Surfactants, used as part of a formulation or alone

Definitions

  • the present invention relates to systems and methods for reduction and control of bacterial biofilm. More particularly, the present invention relates to systems and methods for reduction of biofilms in crossflow filtration systems.
  • Biofilms are formed when colonies of bacteria aggregate on surfaces in many different locations. When bacteria in biofilm aggregate, they produce a sugary, polysaccharide-containing mucous coating, or slime. Bacteria grow and multiply faster when attached (sessile) than when free-floating (planktonic). Within the slime, the bacteria form complex communities with intricate architecture including columns, water channels, and mushroomlike towers. These structural details are believed to improve biofilm nutrient uptake and waste elimination, as blood vessels do in an animal's body.
  • Biofilms occur in a wide range of locations. Many are found on or in the human body, including on the teeth, gums, ears, prostate, lungs, and heart, where they are believed to be implicated in chronic infections such as gum disease, ear infections, infections of the prostate gland and heart, and lung infections in people with cystic fibrosis.
  • Biofilms also occur in nature, such as the slime that covers river rocks, marshes, and the like. Biofilms also occur in medical equipment, such as catheters, and are a major source of hospital infections. Biofilms can also occur in areas such as contact lenses, other medical equipment, and in other industries. A primary difficulty with biofilms is that they are more difficult to reduce or eliminate than are individual bacteria. This is due to the formation of the protective layer of slime, as well as adaptations that the individual bacteria undergo when they form biofilms.
  • Microfiltration membranes are typically polymer or metal membrane disc or pleated cartridge filters rated in the 0.1 to 2 micron range that operate in the 1 to 25 psig pressure range.
  • Ultrafiltration is a crossflow process that rejects contaminants (including organics, bacteria, and pyrogens) in the 10 angstrom to 0.1 micron range using operating pressure in the 10 to 100 psig range.
  • Nanofiltration equipment removes organic compounds in the 200 to 1,000 molecular weight range, rejecting selected salts.
  • Reverse osmosis removes virtually all organic compounds and 90 to 99% of all ions under pressure in the 200 to 1000 psig range.
  • the filtration system Even with continuous dosing methods, at some point the filtration system must be shut down so that the membrane can be cleaned or replaced. This results in downtime and consequent additional operating expense. Moreover, the cleaning and biocidal agents and caustics that are conventionally used to clean and sanitize the filtration systems have the effect of degrading the filter membranes, which are typically comprised of polymers such as cellulose acetate or polyamide polymers. A number of pre-treatment processes are also available to reduce the fouling potential of the feed water being introduced to the membrane. These include various types of filtration, disinfection, and chemical treatment. Even with these methods, however, most RO treatment systems must be cleaned regularly.
  • the present systems and methods are directed to the use of compositions including enzymes and surfactants to obtain biofilm reduction.
  • the enzyme/surfactant compound comprises a blend of enzymes and surfactants over a broad range of compositions and concentrations dependent upon the biofilm treatment application. Additional optional components may include micronutrients that are generated during the enzyme production process or added as additional ingredients. Further optional ingredients in the enzyme/surfactant compound include enzyme stabilizers and anti-microbials to prevent product degradation.
  • the addition of the enzyme/surfactant compound has been found to enhance the effectiveness of crossflow filtration systems, particularly reverse osmosis systems, by increasing throughput, maintaining or improving efficiency, reducing biofilm, decreasing periodic maintenance requirements, and decreasing the need for costly system shutdowns.
  • Figure 1 is a flow diagram illustrating a conventional reverse osmosis filtration system.
  • Figure 2 is a graphical illustration of a membrane showing its function of filtering an aqueous stream containing contaminants.
  • Figure 3 is a graph showing flux vs. time for an aqueous crossflow filtration system.
  • the materials, systems, and methods of the present invention involve the use of an enzyme/surfactant blend compound to reduce biofilms where they occur.
  • the description below will focus on crossflow filtration systems, particularly reverse osmosis systems. It should be understood, however, that the materials, systems, and methods described herein have a broad range of applications, and are not limited solely to filtration systems, crossflow filtration systems, or reverse osmosis filtration systems.
  • FIG 1 is a flow diagram illustrating a conventional reverse osmosis filtration system.
  • Feed water (F) enters a first end of the vessel 10, and concentrate (C) exits from the opposite end of the vessel.
  • a membrane system 12 will typically comprise a plurality of spiral- wound membranes tightly wound within the vessel.
  • a permeate tube 14 is provided at the center of the vessel, surrounded by the membrane system 12. As the feed water (F) enters the vessel 10, it encounters the membrane system 12. The permeate (P) passes through the membranes into the permeate tube 14, where it eventually exits the vessel as indicated in Figure 1.
  • Figure 2 is a graphical illustration of a membrane showing its function of filtering an aqueous stream.
  • the membrane includes a solid barrier 16, usually formed of cellulose acetate, metal, or a polymer such as a polyamide.
  • Sub-microscopic pores 18 are sized to pass water 20 while rejecting oil, dirt, and other contaminants 22. The pores also reject bacteria 24.
  • a properly designed membrane and system allows only desired molecules to pass through the membrane barrier regardless of the feed stream contaminant level.
  • the system performance will deteriorate.
  • the filtration system may require an increased pressure differential to produce the same flux as the system in its "clean" state. Stated otherwise, for the same level of pressure differential, the flux rate of the system will decrease.
  • pressure differential or “Delta Pressure” refers to the difference in pressure between the feed stream (F) and the permeate stream (P)
  • flux refers to the flow rate of the permeate stream (P). This deterioration of performance is illustrated graphically in Figure 3. For each cycle between periodic cleanings, the flux will gradually deteriorate over time as biofilm and other contaminants build up on the membrane system.
  • the enzyme/surfactant compound is a blend of enzymes and surfactants of a range of compositions and concentrations.
  • the basic enzyme/surfactant composition may be supplemented with micronutrients generated during the enzyme production process or added separately. It is also possible to supplement the enzyme/surfactant compound with stabilizers, compounds that give significant stability to the activity of the enzymes.
  • the composition may also optionally be supplemented with anti-microbial agents that inhibit the growth of microbes in its concentrated form.
  • Enzymes degrade pollutants of biological origin, such as fats, oils, proteins and polysaccharides. Other enzymes are known to degrade hydrocarbons. Enzymes pre-digest pollutants so they may be more easily taken up and degraded by bacteria.
  • the enzyme/surfactant compound may contain one purified enzyme or a broad spectrum of enzymes and enzymatic activities. Typical enzymes included in the compound include lipases and esterases, phosphatases, proteases, glycosidases, cellulases, cellobiases, and polysaccharide hydrolases.
  • Enzymes in the compound may also include enzymes with other specificities such as oxidative enzymes, and the composition of an enzyme cocktail used in the compound may be specifically formulated to meet the needs of specific aqueous filtration applications.
  • a nonlimiting list of enzymes and enzyme activities believed to be useful in the enzyme/surfactant compound includes the following: alkaline phosphatase, esterase (C-4), esterase-lipase (C-8), lipase (C-14), leucine arylamidase, valine arylamidase, cystine arylamidase, trypsin, chymotrypsin, acid phosphatase, naphthol-AS-BI-phosphohydrolase, alpha galactosidase, beta galactosidase, beta glucuronidase, alpha glucosidase, N-acetyl-beta- glucosaminidase, alpha mannosidase, and alpha fucosidase
  • the extraction of enzymes from source materials may be enhanced by enzymatic activity. It is a well established practice to effect the release of enzymes from yeast cells by autolysis, that is the use of endogenous (yeast produced) enzymes to break yeast cell membranes.
  • the release of enzymes may also be enhanced by the use of exogenous enzymes. For example, the addition of cellulases to malt increases the yield of other hydrolytic enzymes derived from this source material. Beyond this, methods of obtaining or manufacturing enzymes or enzyme cocktails from these source materials are well-known in the art and are beyond the scope of this discussion, and will therefore not be repeated here. All of the enzymes, endogenous, exogenous, and those released from source materials may be incorporated into the composition so that it has as broad a range of enzymatic activities as possible.
  • the enzyme/surfactant compound includes enzyme activities from Esterases, such as esterase (C-4) and esterase-lipase (C-8); Proteases, such as cystine arylamidase and chymotrypsin; Glycosidases, such as beta galactosidase, beta glucoronidase, beta glucosidase, and alpha mannosidase; and Phosphatases, such as acid phosphatase and naphthol-AS-BI-phosphohydrolase. It is believed that other and further enzymes may further enhance the effectiveness of the enzyme/surfactant compound. Accordingly, this list should be considered illustrative and not limiting.
  • Enzymes may be prepared by a number of methods known to those skilled in the art, including various fermentation processes. Enzymes for use in the enzyme/surfactant compound may be prepared as an enzyme cocktail derived from the fermentation product of molasses and diastatic malt by Saccharomyces cerevisiae. Additional yeast strains that may be used instead of or in addition to Saccharomyces cerevisiae include Kluyveromyces marxianus, Kluyveromyces lactis, Candida utilis (Torula yeast), Zygosaccharomyces, Pichia, Hansanula, and others known to those of skill in the art.
  • Micronutrients may be added to the process, including diammonium phosphate, ammonium sulfate, magnesium sulfate, zinc sulfate and calcium chloride. Additional micronutrients, such as vitamins and amino acids, are produced during the fermentation.
  • Surfactants that are useful in the enzyme/surfactant compound may be either nonionic, anionic, amphoteric or cationic, or a combination of any of the above, depending on the aqueous filtration application.
  • Suitable nonionic surfactants include alkanolamides, amine oxides, block polymers, ethoxylated primary and secondary alcohols, ethoxylated alkylphenols, ethoxylated fatty esters, sorbitan derivatives, glycerol esters, propoxylated and ethoxylated fatty acids, alcohols, and alkyl phenols, glycol esters, polymeric polysaccharides, sulfates and sulfonates of ethoxylated alkylphenols, and polymeric surfactants.
  • Suitable anionic surfactants include ethoxylated amines and/or amides, sulfosuccinates and derivatives, sulfates of ethoxylated alcohols, sulfates of alcohols, sulfonates and sulfonic acid derivatives, phosphate esters, and polymeric surfactants.
  • Suitable amphoteric surfactants include betaine derivatives.
  • Suitable cationic surfactants include amine surfactants. Those skilled in the art will recognize that other and further surfactants are potentially useful in the enzyme/surfactant compound depending on the particular aqueous filtration application.
  • Preferred anionic surfactants used in the enzyme/surfactant compound include CalFoam ES 603, a sodium alcohol ether sulfate surfactant manufactured by Pilot Chemicals Co., and Steol CS 460, a sodium salt of an alkyl ether sulfate manufactured by Stepan Company.
  • Preferred nonionic surfactants used in the enzyme/surfactant compound include Neodol7 25-7 or Neodol7 25-9, which are C 12 -C 15 linear primary alcohol ethoxylates manufactured by Shell Chemical Co., and Genapol7 26 L-60, which is a C 12 -C 16 natural linear alcohol ethoxylated to 60E C cloud point (approx. 7.3 mol), manufactured by Hoechst Celanese Corp. It should be understood that these surfactants and the surfactant classes described above are identified only as preferred materials and that this list is neither exclusive nor limiting of the enzyme/surfactant compound.
  • One or more additional components may optionally be added to the enzyme/surfactant compound in order to stabilize the compound and increase shelf life.
  • additional components may include enzyme stabilizers, anti-microbial agents, and antioxidants.
  • Enzyme stabilizers are effective to extend the enzymatic activity of enzymes.
  • Enzyme stabilizers can include sugars, polyhydrilic alcohols, other organic solvents, ionic or nonionic species, and polymers.
  • An example of a commonly used stabilizer is propylene glycol.
  • anti-microbial agents examples include propylene glycol, methyl paraben, propyl paraben, and sodium benzoate.
  • antioxidants examples include butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), ascorbic acid, and others.
  • the pH of the enzyme/surfactant compound is preferable to adjust the pH of the enzyme/surfactant compound to from about 3.75 to about 5.0, and most preferably to from about 4.2 to about 4.5, with phosphoric acid to help stabilize the product.
  • an enzyme/surfactant compound such as one having the composition listed in Table 2 above, is preferably added to a feed stream at a concentration of about 0.1 parts per million (ppm) to about 25 ppm, depending on the particular application and the contaminants of interest. Higher or lower concentrations may also be possible.
  • a preferred concentration for tertiary treatment of municipal wastewater is from about 0.5 ppm to about 5 ppm, particularly about 3 ppm.
  • a cleaning cycle may be employed wherein the concentration is increased for a period of time.
  • a preferred cleaning cycle includes a concentration of the enzyme/surfactant compound of about 6 to about 25 ppm for a period of from about 3 to about 12 hours.
  • a particularly preferred cycle comprises a concentration of about 9 ppm for a period of about 6 hours.
  • Sludge mass is made up of clumps of bacteria, held together by the sticky polysaccharide biofilm material. During the filtration process, this creates a barrier film that does not allow the water to freely drain from the sludge mass.
  • Sludge was obtained from the Orange County (California, United States) Sanitation District for the study. Testing was conducted to determine TSS (Total Suspended Solids), COD (Chemical Oxygen Demand), and Filtration Characteristics, or water retention. Baseline data, as well as treated and control were recorded, with the following results:
  • the filtrate is the "product" obtained from the permeate in the process.
  • the methods described herein may also be used in applications where the concentrate is the "product.”
  • concentration processes are used to eliminate water from a feed stream.
  • the enzyme/surfactant compound may be used as part of a cleaning cycle to effectively clean filter membranes without damaging them as would be the case with strong acid or caustic cleaning materials.
  • the enzyme/surfactant compound is circulated / recirculated at a concentration of as low as 5-10 ppm to as high as 1% to 5%.
  • the process of concentrating milk causes a significant buildup of not only biofilm on the filter membranes but also significant quantities of butter fat, oil, protein, and other milk constituents.
  • a circulation of a cleaning solution of about 1% to 2% of the enzyme/surfactant compound is utilized at a temperature of 100° F or higher for as little as 10 minutes. Treatments using the enzyme/surfactant compound result in reduced wear and tear on the filter membranes.
  • Yet another application of the enzyme/surfactant compound is in connection with filtration membranes used to eliminate the use of secondary clarifiers in wastewater treatment systems.
  • the enzyme/surfactant compound is introduced in, or prior to, the aeration basin.
  • the filtration membranes are also placed in the aeration basin, but are placed in a quiescent zone within the basin.
  • the benefits of using the enzyme/surfactant compound in these systems are: 1) to increase metabolic activity during the aerobic process, 2) to increase oxygen uptake, thus reducing aeration power requirements and costs, 3) to reduce biomass production, and 4) to reduce or eliminate biofouling of the filtration membranes. Accordingly, the systems and methods described herein achieve improved reduction of biofilms and other benefits. While the above description has focused primarily on crossflow filtration systems, and particularly reverse osmosis systems, it is believed that the enzyme/surfactant compound is useful in reducing biofilms wherever they may occur.

Abstract

The addition of an enzyme/surfactant compound to the feed stream of a crossflow filtration membrane system (12) decreases fouling of the membrane system (12).

Description

SPECIFICATION BIOFILM REDUCTION IN CROSSFLOW FILTRATION SYSTEMS
Field of the Invention The present invention relates to systems and methods for reduction and control of bacterial biofilm. More particularly, the present invention relates to systems and methods for reduction of biofilms in crossflow filtration systems.
Background of the Invention Biofilms are formed when colonies of bacteria aggregate on surfaces in many different locations. When bacteria in biofilm aggregate, they produce a sugary, polysaccharide-containing mucous coating, or slime. Bacteria grow and multiply faster when attached (sessile) than when free-floating (planktonic). Within the slime, the bacteria form complex communities with intricate architecture including columns, water channels, and mushroomlike towers. These structural details are believed to improve biofilm nutrient uptake and waste elimination, as blood vessels do in an animal's body. More information about biofilms is provided in an article entitled "Sticky Situations: Scientists are Beginning to Understand How Bacteria Find Strength in Numbers" by Jessa Netting, published in Science News, 60:28-30, July 14, 2001, which is the basis for the information in this and the following paragraphs, and which is hereby incorporated by reference herein in its entirety. Biofilms occur in a wide range of locations. Many are found on or in the human body, including on the teeth, gums, ears, prostate, lungs, and heart, where they are believed to be implicated in chronic infections such as gum disease, ear infections, infections of the prostate gland and heart, and lung infections in people with cystic fibrosis. Biofilms also occur in nature, such as the slime that covers river rocks, marshes, and the like. Biofilms also occur in medical equipment, such as catheters, and are a major source of hospital infections. Biofilms can also occur in areas such as contact lenses, other medical equipment, and in other industries. A primary difficulty with biofilms is that they are more difficult to reduce or eliminate than are individual bacteria. This is due to the formation of the protective layer of slime, as well as adaptations that the individual bacteria undergo when they form biofilms.
One important area in which biofilms occur is in aqueous systems that use separation membranes, such as particle filtration, microfiltration, ultrafiltration, nanofiltration, and particularly reverse osmosis ("RO") systems. Microfiltration membranes are typically polymer or metal membrane disc or pleated cartridge filters rated in the 0.1 to 2 micron range that operate in the 1 to 25 psig pressure range. Ultrafiltration is a crossflow process that rejects contaminants (including organics, bacteria, and pyrogens) in the 10 angstrom to 0.1 micron range using operating pressure in the 10 to 100 psig range. Nanofiltration equipment removes organic compounds in the 200 to 1,000 molecular weight range, rejecting selected salts. Reverse osmosis removes virtually all organic compounds and 90 to 99% of all ions under pressure in the 200 to 1000 psig range.
These systems use membranes to selectively remove or separate extremely small substances from water and process streams in residential, commercial, and industrial applications. When biofilm is present on the membrane due to microbial growth, colloidal solids and insoluble precipitates can adhere to the sticky substance. As this combination builds, water transmission rates through the membrane are reduced and/or additional pressure must be applied to maintain the same water transmission rates. Colloidal solids, microbiological growth, and insoluble precipitates can collect on the membrane during operation. Conventional treatment methods include continuous dosing, in which a residual level of a biocidal agent is maintained within the system, or periodic cleaning and sanitization, in which the filtration system is shut down for a periodic cleaning and sanitization using biocidal agents, acids and caustics. Even with continuous dosing methods, at some point the filtration system must be shut down so that the membrane can be cleaned or replaced. This results in downtime and consequent additional operating expense. Moreover, the cleaning and biocidal agents and caustics that are conventionally used to clean and sanitize the filtration systems have the effect of degrading the filter membranes, which are typically comprised of polymers such as cellulose acetate or polyamide polymers. A number of pre-treatment processes are also available to reduce the fouling potential of the feed water being introduced to the membrane. These include various types of filtration, disinfection, and chemical treatment. Even with these methods, however, most RO treatment systems must be cleaned regularly.
Accordingly, there exists a long-felt need for improved treatment processes that can achieve reductions in biofilm, particularly in the area of aqueous systems that use separation membranes.
Summary of the invention
The present systems and methods are directed to the use of compositions including enzymes and surfactants to obtain biofilm reduction. The enzyme/surfactant compound comprises a blend of enzymes and surfactants over a broad range of compositions and concentrations dependent upon the biofilm treatment application. Additional optional components may include micronutrients that are generated during the enzyme production process or added as additional ingredients. Further optional ingredients in the enzyme/surfactant compound include enzyme stabilizers and anti-microbials to prevent product degradation.
The addition of the enzyme/surfactant compound has been found to enhance the effectiveness of crossflow filtration systems, particularly reverse osmosis systems, by increasing throughput, maintaining or improving efficiency, reducing biofilm, decreasing periodic maintenance requirements, and decreasing the need for costly system shutdowns.
It is thus an object of this invention to provide systems and methods for reducing biofilms.
It is a further object of this invention to provide systems and methods for improving the performance of aqueous systems that use separation membranes, thus enhancing the separation process of such systems.
It is a still further object of this invention to provide systems and methods for reducing biofilm and other fouling agents in crossflow filtration systems, thus enhancing the filtration process. It is a still further object of this invention to provide improved aqueous filtration systems and methods that reduce fouling.
These and further objects and advantages will become apparent upon consideration of the detailed description and drawings enclosed herein.
Brief Description of the Drawings
Figure 1 is a flow diagram illustrating a conventional reverse osmosis filtration system. Figure 2 is a graphical illustration of a membrane showing its function of filtering an aqueous stream containing contaminants.
Figure 3 is a graph showing flux vs. time for an aqueous crossflow filtration system.
Detailed Description of the Preferred Embodiments The materials, systems, and methods of the present invention involve the use of an enzyme/surfactant blend compound to reduce biofilms where they occur. The description below will focus on crossflow filtration systems, particularly reverse osmosis systems. It should be understood, however, that the materials, systems, and methods described herein have a broad range of applications, and are not limited solely to filtration systems, crossflow filtration systems, or reverse osmosis filtration systems.
Figure 1 is a flow diagram illustrating a conventional reverse osmosis filtration system. Feed water (F) enters a first end of the vessel 10, and concentrate (C) exits from the opposite end of the vessel. A membrane system 12 will typically comprise a plurality of spiral- wound membranes tightly wound within the vessel. A permeate tube 14 is provided at the center of the vessel, surrounded by the membrane system 12. As the feed water (F) enters the vessel 10, it encounters the membrane system 12. The permeate (P) passes through the membranes into the permeate tube 14, where it eventually exits the vessel as indicated in Figure 1. Figure 2 is a graphical illustration of a membrane showing its function of filtering an aqueous stream. The membrane includes a solid barrier 16, usually formed of cellulose acetate, metal, or a polymer such as a polyamide. Sub-microscopic pores 18 are sized to pass water 20 while rejecting oil, dirt, and other contaminants 22. The pores also reject bacteria 24. A properly designed membrane and system allows only desired molecules to pass through the membrane barrier regardless of the feed stream contaminant level.
As biofilm or other contaminants build up on a membrane system, the system performance will deteriorate. For example, the filtration system may require an increased pressure differential to produce the same flux as the system in its "clean" state. Stated otherwise, for the same level of pressure differential, the flux rate of the system will decrease. For these purposes, the term "pressure differential" or "Delta Pressure" refers to the difference in pressure between the feed stream (F) and the permeate stream (P), and "flux" refers to the flow rate of the permeate stream (P). This deterioration of performance is illustrated graphically in Figure 3. For each cycle between periodic cleanings, the flux will gradually deteriorate over time as biofilm and other contaminants build up on the membrane system. The periodic cleaning will cause the flux level to increase, although typically not to its peak level from the previous cycle because the membrane will generally degrade due to use and, in most circumstances, due to the cleaning process. Thus, in addition to the fluctuations of the system flux between periodic cleanings, there will also be an observed general decline in system performance over time, as illustrated in the parallel downward sloping phantom lines in Figure 3.
It has been found that the addition of an enzyme/surfactant compound to the feed stream (F) has the effect of decreasing fouling of the filter system, and enhancing the filtration and concentration processes of conventional filtration systems. The enzyme/surfactant compound is a blend of enzymes and surfactants of a range of compositions and concentrations. The basic enzyme/surfactant composition may be supplemented with micronutrients generated during the enzyme production process or added separately. It is also possible to supplement the enzyme/surfactant compound with stabilizers, compounds that give significant stability to the activity of the enzymes. The composition may also optionally be supplemented with anti-microbial agents that inhibit the growth of microbes in its concentrated form.
Enzymes degrade pollutants of biological origin, such as fats, oils, proteins and polysaccharides. Other enzymes are known to degrade hydrocarbons. Enzymes pre-digest pollutants so they may be more easily taken up and degraded by bacteria. In its preferred form, the enzyme/surfactant compound may contain one purified enzyme or a broad spectrum of enzymes and enzymatic activities. Typical enzymes included in the compound include lipases and esterases, phosphatases, proteases, glycosidases, cellulases, cellobiases, and polysaccharide hydrolases. Enzymes in the compound may also include enzymes with other specificities such as oxidative enzymes, and the composition of an enzyme cocktail used in the compound may be specifically formulated to meet the needs of specific aqueous filtration applications. A nonlimiting list of enzymes and enzyme activities believed to be useful in the enzyme/surfactant compound includes the following: alkaline phosphatase, esterase (C-4), esterase-lipase (C-8), lipase (C-14), leucine arylamidase, valine arylamidase, cystine arylamidase, trypsin, chymotrypsin, acid phosphatase, naphthol-AS-BI-phosphohydrolase, alpha galactosidase, beta galactosidase, beta glucuronidase, alpha glucosidase, N-acetyl-beta- glucosaminidase, alpha mannosidase, and alpha fucosidase.
There are a great many materials derived from plant, animal, and microbial sources that have been known to those skilled in the art to be rich sources of enzymes. These source materials may be used with full, partial, or no purification of enzymes to obtain enzymes for use in the enzyme/surfactant compound. Some of these sources of enzymes are provided in Table 1 below. Additional information concerning the sources of enzymes useful in the enzyme/surfactant compound may be found in: Thomas E. Barman, Enzyme Handbook. Nols. I-II (Springer-Nerlag, New York 1969); Dixon and Webb, Enzymes, pp. 671-785 (Academic Press Inc., 1964); Kornberg, For the Love of Enzymes: The Odyssey of a Biochemist, p. 37 (Harvard University Press, 1989); Fruton and Sinrmonds, General Biochemistry, pp. 218-219 (John Wiley and Sons, 2nd Ed. 1958); U.S. Patent No. 4,891,320 to Aust et al; and U.S. Patent No. 3,635,797 to Battistoni et al. Each of these publications is hereby incorporated by reference herein in its entirety.
TABLE 1
Figure imgf000008_0001
The extraction of enzymes from source materials may be enhanced by enzymatic activity. It is a well established practice to effect the release of enzymes from yeast cells by autolysis, that is the use of endogenous (yeast produced) enzymes to break yeast cell membranes. The release of enzymes may also be enhanced by the use of exogenous enzymes. For example, the addition of cellulases to malt increases the yield of other hydrolytic enzymes derived from this source material. Beyond this, methods of obtaining or manufacturing enzymes or enzyme cocktails from these source materials are well-known in the art and are beyond the scope of this discussion, and will therefore not be repeated here. All of the enzymes, endogenous, exogenous, and those released from source materials may be incorporated into the composition so that it has as broad a range of enzymatic activities as possible.
In a preferred form, the enzyme/surfactant compound includes enzyme activities from Esterases, such as esterase (C-4) and esterase-lipase (C-8); Proteases, such as cystine arylamidase and chymotrypsin; Glycosidases, such as beta galactosidase, beta glucoronidase, beta glucosidase, and alpha mannosidase; and Phosphatases, such as acid phosphatase and naphthol-AS-BI-phosphohydrolase. It is believed that other and further enzymes may further enhance the effectiveness of the enzyme/surfactant compound. Accordingly, this list should be considered illustrative and not limiting.
Enzymes may be prepared by a number of methods known to those skilled in the art, including various fermentation processes. Enzymes for use in the enzyme/surfactant compound may be prepared as an enzyme cocktail derived from the fermentation product of molasses and diastatic malt by Saccharomyces cerevisiae. Additional yeast strains that may be used instead of or in addition to Saccharomyces cerevisiae include Kluyveromyces marxianus, Kluyveromyces lactis, Candida utilis (Torula yeast), Zygosaccharomyces, Pichia, Hansanula, and others known to those of skill in the art. Micronutrients may be added to the process, including diammonium phosphate, ammonium sulfate, magnesium sulfate, zinc sulfate and calcium chloride. Additional micronutrients, such as vitamins and amino acids, are produced during the fermentation.
Surfactants that are useful in the enzyme/surfactant compound may be either nonionic, anionic, amphoteric or cationic, or a combination of any of the above, depending on the aqueous filtration application. Suitable nonionic surfactants include alkanolamides, amine oxides, block polymers, ethoxylated primary and secondary alcohols, ethoxylated alkylphenols, ethoxylated fatty esters, sorbitan derivatives, glycerol esters, propoxylated and ethoxylated fatty acids, alcohols, and alkyl phenols, glycol esters, polymeric polysaccharides, sulfates and sulfonates of ethoxylated alkylphenols, and polymeric surfactants. Suitable anionic surfactants include ethoxylated amines and/or amides, sulfosuccinates and derivatives, sulfates of ethoxylated alcohols, sulfates of alcohols, sulfonates and sulfonic acid derivatives, phosphate esters, and polymeric surfactants. Suitable amphoteric surfactants include betaine derivatives. Suitable cationic surfactants include amine surfactants. Those skilled in the art will recognize that other and further surfactants are potentially useful in the enzyme/surfactant compound depending on the particular aqueous filtration application.
Preferred anionic surfactants used in the enzyme/surfactant compound include CalFoam ES 603, a sodium alcohol ether sulfate surfactant manufactured by Pilot Chemicals Co., and Steol CS 460, a sodium salt of an alkyl ether sulfate manufactured by Stepan Company. Preferred nonionic surfactants used in the enzyme/surfactant compound include Neodol7 25-7 or Neodol7 25-9, which are C12-C15 linear primary alcohol ethoxylates manufactured by Shell Chemical Co., and Genapol7 26 L-60, which is a C12-C16 natural linear alcohol ethoxylated to 60E C cloud point (approx. 7.3 mol), manufactured by Hoechst Celanese Corp. It should be understood that these surfactants and the surfactant classes described above are identified only as preferred materials and that this list is neither exclusive nor limiting of the enzyme/surfactant compound.
One or more additional components may optionally be added to the enzyme/surfactant compound in order to stabilize the compound and increase shelf life. Such additional components may include enzyme stabilizers, anti-microbial agents, and antioxidants.
Enzyme stabilizers are effective to extend the enzymatic activity of enzymes. Enzyme stabilizers can include sugars, polyhydrilic alcohols, other organic solvents, ionic or nonionic species, and polymers. An example of a commonly used stabilizer is propylene glycol.
Examples of anti-microbial agents that may be used in the enzyme/surfactant compound include propylene glycol, methyl paraben, propyl paraben, and sodium benzoate.
Examples of antioxidants that may be incorporated into the enzyme/surfactant compound include butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), ascorbic acid, and others.
It is preferable to adjust the pH of the enzyme/surfactant compound to from about 3.75 to about 5.0, and most preferably to from about 4.2 to about 4.5, with phosphoric acid to help stabilize the product. In particular, it is beneficial to make the compound acidic in order to optimize the activity of the anti-microbial agents, such as methyl or propyl paraben.
A preferred composition of an enzyme/surfactant compound useful in the systems and methods described herein is provided in Table 2 below. TABLE 2
Figure imgf000011_0001
To achieve reduction of biofilm and other contaminants in a reverse osmosis or other aqueous crossflow filtration system, an enzyme/surfactant compound, such as one having the composition listed in Table 2 above, is preferably added to a feed stream at a concentration of about 0.1 parts per million (ppm) to about 25 ppm, depending on the particular application and the contaminants of interest. Higher or lower concentrations may also be possible. A preferred concentration for tertiary treatment of municipal wastewater is from about 0.5 ppm to about 5 ppm, particularly about 3 ppm. A cleaning cycle may be employed wherein the concentration is increased for a period of time. A preferred cleaning cycle includes a concentration of the enzyme/surfactant compound of about 6 to about 25 ppm for a period of from about 3 to about 12 hours. A particularly preferred cycle comprises a concentration of about 9 ppm for a period of about 6 hours.
Experiments have shown that the use of the enzyme/surfactant compound increases system performance by preventing fouling due to biofilm and other contaminants. This result has been observed in two ways. Referring once again to Figure 3, first, the flux rate between system cleaning cycles has been observed to decrease less through use of the enzyme/surfactant compound. Second, the overall system performance has been observed to degrade significantly less when the enzyme/surfactant compound has been used. It is believed that the increased system performance may be due, at least in part, to a breakdown of the sticky polysaccharide biofilm material.
For example, studies were conducted to determine the effects of treating sludge with the composition listed as the "Preferred Concentration" in Table 2. Sludge mass is made up of clumps of bacteria, held together by the sticky polysaccharide biofilm material. During the filtration process, this creates a barrier film that does not allow the water to freely drain from the sludge mass. Sludge was obtained from the Orange County (California, United States) Sanitation District for the study. Testing was conducted to determine TSS (Total Suspended Solids), COD (Chemical Oxygen Demand), and Filtration Characteristics, or water retention. Baseline data, as well as treated and control were recorded, with the following results:
Figure imgf000012_0001
Figure imgf000013_0001
While the TSS levels were reduced by 7 % for both the Treated and Control from the Baseline, the permeate from the Treated sample exhibited an increase in COD of 18.3 % over the Control. It is assumed that the reduction in TSS occurred due to a decay of the actual cells or walls. However, the COD results, in conjunction with the significant reduction of sludge volume for the Treated sample vis-a-vis the Control, establish that channeling in the sludge matrix is improved, allowing the water to drain through (or around) the bacterial cell matter. This is due to the breakdown of the sticky polysaccharide biofilm material. The foregoing descriptions include a detailed description of the use of an enzyme/surfactant compound for the treatment of wastewater or drinking water in crossflow filtration systems. One example of such systems is water desalination. It has been found that the enzyme / surfactant compound, when used in a water desalination process, improves the efficiency of the desalination process.
In the wastewater or drinking water systems and methods described herein, the filtrate is the "product" obtained from the permeate in the process. As yet another example, the methods described herein may also be used in applications where the concentrate is the "product." For example, in the dairy, fruit juice, or other industries, concentration processes are used to eliminate water from a feed stream. In those types of systems and methods, the enzyme/surfactant compound may be used as part of a cleaning cycle to effectively clean filter membranes without damaging them as would be the case with strong acid or caustic cleaning materials. In those systems and methods, the enzyme/surfactant compound is circulated / recirculated at a concentration of as low as 5-10 ppm to as high as 1% to 5%. The actual use levels would be highly dependent on the nature of the foulant, time limits for the cleaning cycle, temperatures of the cleaning solutions, filter membrane construction and/or materials, filter type (micro, ultra, nano, or reverse osmosis), and other factors. As a non- limiting example, the process of concentrating milk causes a significant buildup of not only biofilm on the filter membranes but also significant quantities of butter fat, oil, protein, and other milk constituents. In that example, a circulation of a cleaning solution of about 1% to 2% of the enzyme/surfactant compound is utilized at a temperature of 100° F or higher for as little as 10 minutes. Treatments using the enzyme/surfactant compound result in reduced wear and tear on the filter membranes.
Yet another application of the enzyme/surfactant compound is in connection with filtration membranes used to eliminate the use of secondary clarifiers in wastewater treatment systems. In such systems, the enzyme/surfactant compound is introduced in, or prior to, the aeration basin. The filtration membranes are also placed in the aeration basin, but are placed in a quiescent zone within the basin. The benefits of using the enzyme/surfactant compound in these systems are: 1) to increase metabolic activity during the aerobic process, 2) to increase oxygen uptake, thus reducing aeration power requirements and costs, 3) to reduce biomass production, and 4) to reduce or eliminate biofouling of the filtration membranes. Accordingly, the systems and methods described herein achieve improved reduction of biofilms and other benefits. While the above description has focused primarily on crossflow filtration systems, and particularly reverse osmosis systems, it is believed that the enzyme/surfactant compound is useful in reducing biofilms wherever they may occur.
Thus, the compounds, systems and methods of the present invention provide many benefits over the prior art. While the above description contains many specificities, these should not be construed as limitations on the scope of the invention, but rather as an exemplification of the preferred embodiments thereof. Many other variations are possible.
Accordingly, the scope of the present invention should be determined not by the embodiments illustrated above, but by the appended claims and their legal equivalents.

Claims

What is claimed is:
1. A method for reducing biofilm in an aqueous system, comprising the steps of: providing a mixture containing enzymes and surfactants, and introducing the mixture to an aqueous system containing biofilm.
2. The method of claim 1, wherein said mixture comprises enzymes from one or more of the classes including esterases, Upases, proteases, glycosidases, cellulases, cellobiases, and phosphatases.
3. The method of claim 2, wherein said mixture comprises lysozyme.
4. The method of claim 2, wherein said mixture comprises esterase (C-4), esterase-lipase (C-8), cystine arylamidase, chymotrypsin, beta galactosidase, beta glucuronidase, and naphthol-AS-BI-phosphohydrolase.
5. The method of claim 1, wherein said mixture comprises nonionic surfactants from one or more of the classes including alkanolamides, amine oxides, block polymers, ethoxylated primary and secondary alcohols, ethoxylated alkylphenols, ethoxylated fatty esters, sorbitan derivatives, glycerol esters, and polymeric surfactants.
6. The method of claim 5, wherein said mixture comprises a C12-Cι6 linear alcohol ethoxylate surfactant.
7. The method of claim 1, wherein said mixture comprises anionic surfactants from one or more of the classes including ethoxylated amines, ethoxylated amides, sulfosuccinates and derivatives, sulfates of ethoxylated alcohols, sulfates of alcohols, and polymeric surfactants.
8. The method of claim 7, wherein said mixture comprises a sodium alkyl ether sulfate surfactant.
9. The method of claim 1, wherein said mixture comprises the fermentation product of a yeast selected from the group consisting of Saccharomyces cerevisiae,
Kluyveromyces marxianus, Kluyveromyces lactis, Candida utilis (Torula yeast), Zygosaccharomyces, Pichia, and Hansanula.
10. The method of claim 9, wherein said mixture further comprises one or more nonionic surfactants from the group comprising alkanolamides, amine oxides, block polymers, ethoxylated primary and secondary alcohols, ethoxylated alkylphenols, ethoxylated fatty esters, sorbitan derivatives, glycerol esters, and polymeric surfactants.
11. The method of claim 9, wherein said mixture further comprises one or more anionic surfactants from the group comprising ethoxylated amines, ethoxylated amides, sulfosuccinates and derivatives, sulfates of ethoxylated alcohols, sulfates of alcohols, and polymeric surfactants.
12. The method of claim 9, wherein said mixture further comprises a C12-C16 linear alcohol ethoxylate surfactant and a sodium alkyl ether sulfate surfactant.
13. The method of claim 12, wherein said fermentation product is present in said mixture at a concentration of from about 5.0% by weight to about 60.0% by weight, and said mixture is added to the aqueous system to obtain a concentration by weight of the mixture of from about 0.1 part per million to about 25 parts per million.
14. The method of claim 12, wherein said fermentation product is present in said mixture at a concentration of from about 5.0%) by weight to about 50.0%> by weight, and said mixture is added to the aqueous system to obtain a concentration by weight of the mixture of from about 1 parts per million to about 5 parts per million.
15. The method of claim 1, wherein said aqueous system is a crossflow filtration system. .
16. The method of claim 15 wherein said crossflow filtration system is a reverse osmosis system.
17. The method of claim 15, wherein said mixture comprises the fermentation product of a yeast selected from the group consisting of Saccharomyces cerevisiae, Kluyveromyces marxianus, Kluyveromyces lactis, Candida utilis (Torula yeast), Zygosaccharomyces, Pichia, and Hansanula.
18. The method of claim 17, wherein said mixture further comprises one or more nonionic surfactants from the group comprising alkanolamides, amine oxides, block polymers, ethoxylated primary and secondary alcohols, ethoxylated alkylphenols, ethoxylated fatty esters, sorbitan derivatives, glycerol esters, and polymeric surfactants.
19. The method of claim 17, wherein said mixture further comprises one or more anionic surfactants from the group comprising ethoxylated amines, ethoxylated amides, sulfosuccinates and derivatives, sulfates of ethoxylated alcohols, sulfates of alcohols, and polymeric surfactants.
20. The method of claim 17, wherein said mixture further comprises a C12-C16 linear alcohol ethoxylate surfactant and a sodium alkyl ether sulfate surfactant.
21. The method of claim 20, wherein said fermentation product is present in said mixture at a concentration of from about 5.0%> by weight to about 60.0% by weight, and said mixture is added to the reverse osmosis system to obtain a concentration by weight of the mixture of from about 0.1 part per million to about 25 parts per million.
22. The method of claim 20, wherein said fermentation product is present in said mixture at a concentration of from about 5.0%> by weight to about 60.0% by weight, and said mixture is added to the reverse osmosis system to obtain a concentration by weight of the mixture of from about 1 parts per million to about 5 parts per million.
23. The method of claim 12, wherein said fermentation product is present in said mixture at a concentration of from about 5.0% by weight to about 60.0% by weight, and said mixture is added to the aqueous system to obtain a concentration by weight of the mixture of from about 1%> to about 2%>.
24. The method of claim 23 wherein the system temperature is 100° F or higher.
25. The method of claim 24 comprising the additional step of removing the mixture containing enzymes and surfactants from the aqueous system within 10 minutes of said introducing step.
PCT/US2002/027612 2001-09-07 2002-08-30 Biofilm reduction in crossflow filtration systems WO2003022752A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP02757479A EP1423337A4 (en) 2001-09-07 2002-08-30 Biofilm reduction in crossflow filtration systems

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/948,457 US6699391B2 (en) 2001-09-07 2001-09-07 Biofilm reduction in crossflow filtration systems
US09/948,457 2001-09-07

Publications (2)

Publication Number Publication Date
WO2003022752A1 WO2003022752A1 (en) 2003-03-20
WO2003022752A9 true WO2003022752A9 (en) 2004-03-18

Family

ID=25487874

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/027612 WO2003022752A1 (en) 2001-09-07 2002-08-30 Biofilm reduction in crossflow filtration systems

Country Status (3)

Country Link
US (2) US6699391B2 (en)
EP (1) EP1423337A4 (en)
WO (1) WO2003022752A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19937300A1 (en) * 1999-08-06 2001-02-22 Henkel Ecolab Gmbh & Co Ohg Biofilm avoidance
US6699391B2 (en) * 2001-09-07 2004-03-02 Advanced Biocatalytics Corporation Biofilm reduction in crossflow filtration systems
WO2004081034A2 (en) * 2003-03-11 2004-09-23 Advanced Biocatalytics Corporation Altering metabolism in biological processes
US7488757B2 (en) 2003-03-24 2009-02-10 Becton, Dickinson And Company Invisible antimicrobial glove and hand antiseptic
US8795740B2 (en) * 2003-10-24 2014-08-05 Novapharm Research (Australia) Pty Ltd Drip tray tablet
US7220358B2 (en) * 2004-02-23 2007-05-22 Ecolab Inc. Methods for treating membranes and separation facilities and membrane treatment composition
US7645730B2 (en) * 2004-04-29 2010-01-12 Advanced Biocatalytics Corp. Surfactant composition with a reduction of surface tension, interfacial tension, and critical micelle concentration using a protein-based surfactant synergist
US20060051339A1 (en) * 2004-09-08 2006-03-09 Sivak Hannah N Composition for treatment of oily skin and acne prevention and methods of making and using same
US20060201877A1 (en) * 2005-03-10 2006-09-14 Baldridge John W Septic system cleaning
US8038990B2 (en) * 2005-06-01 2011-10-18 The Ohio State University Compositions and methods for the prevention and removal of biofilms on inert and biological surfaces
US20070045187A1 (en) * 2005-09-01 2007-03-01 Rawson James R Y Biofouling control of membrane water-purification systems
JP2007160242A (en) * 2005-12-15 2007-06-28 Japan Organo Co Ltd Ballast water preparation apparatus, ship equipped with it, and ballast water preparation method
CN101437393B (en) * 2006-03-23 2014-03-12 花王株式会社 Biofilm formation inhibitor composition
CN101448399B (en) * 2006-04-21 2013-06-05 花王株式会社 Composition of biofilm control agent
WO2008086221A2 (en) * 2007-01-04 2008-07-17 Advanced Biocatalytics Corporation Enhanced oil recovery compositions comprising proteins and surfactants and methods of using the same
US8101083B2 (en) * 2007-08-20 2012-01-24 Earth Renaissance Technologies, Llc Pre-treatment reverse osmosis water recovery method for brine retentate metals removal
US8236178B2 (en) * 2007-08-20 2012-08-07 Earth Renaissance Technologies, Llc Reverse osmosis water recover method
US20090050563A1 (en) * 2007-08-20 2009-02-26 Earth Renaissance Technologies, Llc. Treatment method for reverse osmosis filtration systems
CA2739692A1 (en) * 2008-10-16 2010-04-22 Advanced Biocatalytics Corporation Enhanced performance hydrogen peroxide formulations comprising proteins and surfactants
CA2745671A1 (en) 2008-12-12 2010-06-17 Advanced Biocatalytics Corporation Protein compositions for plant treatment
CA2753361A1 (en) 2009-02-09 2010-08-12 Advanced Biocatalytics Corporation Cleaning compositions and methods for burnt-on food and oil residues
JP2011083732A (en) * 2009-10-16 2011-04-28 Mimaki Engineering Co Ltd Wastewater purifying system, cleaning device and ink jet printer system
CA2803082A1 (en) * 2010-06-24 2011-12-29 Richcore Lifesciences Pvt. Ltd. A method for rapid treatment of waste water and a composition thereof
KR101246117B1 (en) 2011-07-04 2013-03-21 서울대학교산학협력단 Membrane with immobilized enzyme for inhibiting biofilm formation, process for preparing the same and water treatment process using the same
US9352284B2 (en) * 2011-07-22 2016-05-31 Purdue Research Foundation Enzymatic treatment of alginate to reduce membrane fouling for water or wastewater purification
US9051535B2 (en) 2012-03-26 2015-06-09 Advanced Biocatalytics Corporation Protein-enhanced surfactants for enzyme activation
EP2666755A1 (en) * 2012-05-25 2013-11-27 Kemira Oyj Water treatment method comprising addition of surfactant before reverse osmosis filtration
US10557234B2 (en) 2012-05-29 2020-02-11 Neozyme International, Inc. Papermaking additive compositions and methods and uses thereof
ES2831372T3 (en) 2012-05-29 2021-06-08 Neozyme Int Inc A useful biocatalytic composition in soil conditioning
US10334856B2 (en) 2012-05-29 2019-07-02 Neozyme International, Inc. Non-toxic pest control compositions and methods and uses thereof
US10681914B2 (en) 2012-05-29 2020-06-16 Neozyme International, Inc. Non-toxic plant agent compositions and methods and uses thereof
MX369146B (en) * 2012-07-13 2019-10-30 Basf Se Use of alkoxylated non-ionic surfactants as additive in aqueous membrane cleaning compositions.
CN105152310B (en) * 2015-09-22 2017-05-10 南京大学 In-situ excitation method of biological aerated filter aged biological film
CN105169953A (en) * 2015-09-29 2015-12-23 唐山沃德环保技术有限公司 Enzyme cleaning agent for removing reverse osmosis membrane microbial contaminants and use method thereof
CN105753142B (en) * 2016-04-18 2019-03-26 南京大学 A kind of the in-situ activation agent and in-situ activation method of aerating biological filter pool filler biomembrane
MX2022010580A (en) 2020-02-28 2022-09-09 Catexel Tech Limited Degradative method.
US11932795B2 (en) 2020-06-03 2024-03-19 Ecolab Usa Inc. Aromatic amine epoxide adducts for corrosion inhibition
CA3181256A1 (en) 2020-06-03 2021-12-09 Sukhwan Soontravanich Non-caustic cleaning methods and uses

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2320479A (en) * 1939-06-19 1943-06-01 Inst Divi Thomae Foundation Topical remedy
US3404068A (en) * 1966-12-01 1968-10-01 Zymak Biochemical Corp Composition for compacting soil
US3635797A (en) * 1968-11-18 1972-01-18 Nevada Enzymes Inc Enzymatic composition
GB2054643B (en) * 1979-07-18 1983-05-05 Rolls Royce Fermentation process for the manufacture of an organic compound
JPS6456889A (en) * 1987-08-28 1989-03-03 Sumitomo Chemical Co Method for removing scale in jacket of glass lined apparatus
US5023090A (en) * 1989-08-16 1991-06-11 Levin Robert H Topical compositions containing LYCD and other topically active medicinal ingredients for the treatment of ACNE
US5238925A (en) * 1990-05-09 1993-08-24 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Angiogenic factor isolated from live yeast cell derivatives and its use in treating wounds or burns in mammals
ES2078738T3 (en) 1991-02-12 1995-12-16 Buckman Labor Inc COMPOSITION AND PROCEDURE TO ELIMINATE OR PREVENT THE APPEARANCE OF BIOFILMS.
CA2106609A1 (en) * 1992-09-28 1994-03-29 Irene Yeatman Aldridge Proteases to inhibit and remove biofilm
JP3510258B2 (en) * 1993-05-03 2004-03-22 ミネソタ マイニング アンド マニュファクチャリング カンパニー Reinforcing elements for castable compositions
US5731275A (en) * 1994-04-05 1998-03-24 Universite De Montreal Synergistic detergent and disinfectant combinations for decontaminating biofilm-coated surfaces
US5663134A (en) 1994-08-12 1997-09-02 The Procter & Gamble Company Composition for reducing malodor impression on inanimate surfaces
US5593670A (en) 1994-08-12 1997-01-14 The Proctor & Gamble Company Uncomplexed cyclodextrin solutions for odor control on inanimate surfaces
EP0779927A1 (en) * 1994-09-08 1997-06-25 Chiron Corporation A method of improved production of insulin-like growth factor
US5789239A (en) * 1995-06-05 1998-08-04 Betzdearborn Inc. Composition and process for the avoidance of slime formation and/or for the removal of biofilm in water-bearing systems
US5879928A (en) 1995-10-31 1999-03-09 Neozyme International, Inc. Composition for the treatment for municipal and industrial waste-water
WO1997026855A1 (en) * 1996-01-24 1997-07-31 Warner-Lambert Company Peroxide/essential oils containing mouthwash compositions and two-part mouthwash systems
US5885950A (en) 1996-01-31 1999-03-23 Neozyme International, Inc. Composition for cleaning grease-traps and septic tanks control
US5820758A (en) 1996-01-31 1998-10-13 Neozyme International, Inc. Composition and method for clarifying and deodorizing a standing body of water
US5849566A (en) 1997-01-23 1998-12-15 Neozyme International, Inc. Composition for accelerating the decomposition of hydrocarbons
US5670055A (en) * 1996-08-08 1997-09-23 Nalco Chemical Company Use of the linear alkylbenzene sulfonate as a biofouling control agent
US5882530A (en) * 1997-04-30 1999-03-16 The University Of Akron Crossflow filter cyclone apparatus
US6454871B1 (en) * 1997-06-23 2002-09-24 Princeton Trade & Technology, Inc. Method of cleaning passageways using a mixed phase flow of gas and a liquid
JPH11256081A (en) * 1998-03-10 1999-09-21 Seiko Epson Corp Recording fluid
US6358914B1 (en) * 1999-06-17 2002-03-19 Gladys S. Gabriel Surfactant compositions with enhanced soil release properties containing a cationic gemini surfactant
ES2162593B1 (en) * 2000-01-20 2002-07-01 Univ Madrid Complutense ENZYMATIC PROCEDURE TO FLUIDIFY OR UNLOCK BIOFILMS OF DIFFERENT INTERFACES.
US20030022280A1 (en) * 2000-03-10 2003-01-30 Novozymes A/S Compositions and methods for producing high yields of heterologous polypeptides in a pichia cell
WO2001094513A1 (en) * 2000-06-05 2001-12-13 S. C. Johnson & Son, Inc. Biocidal cleaner composition
US6699391B2 (en) * 2001-09-07 2004-03-02 Advanced Biocatalytics Corporation Biofilm reduction in crossflow filtration systems

Also Published As

Publication number Publication date
US7165561B2 (en) 2007-01-23
WO2003022752A1 (en) 2003-03-20
EP1423337A4 (en) 2005-08-24
US6699391B2 (en) 2004-03-02
EP1423337A2 (en) 2004-06-02
US20030047510A1 (en) 2003-03-13
US20040217052A1 (en) 2004-11-04

Similar Documents

Publication Publication Date Title
US7165561B2 (en) Biofilm reduction in crossflow filtration systems
Anand et al. Development and control of bacterial biofilms on dairy processing membranes
Griebe et al. Biocide-free antifouling strategy to protect RO membranes from biofouling
AU2005254342B2 (en) Process for recovering the components of olive mill wastewater with membrane technologies
Shivajirao Treatment of distillery wastewater using membrane technologies
JP2018089627A (en) Methods, compositions and systems for controlling fouling of membrane
CN104911130B (en) One plant of Halomonas with denitrification ability and its application
CN103025668A (en) A method for rapid treatment of waste water and a composition thereof
Kim et al. Assessing the effects of bacterial predation on membrane biofouling
Flemming et al. Effects and extent of biofilm accumulation in membrane systems
Xu et al. Evaluation of high density algal cultivation for secondary wastewater polishing
Ritambhara et al. Treatment and Recycling of wastewater from dairy industry
Khan et al. Enzymatic cleaning of biofouled thin-film composite reverse osmosis (RO) membrane operated in a biofilm membrane reactor
Zahmatkesh et al. Wastewater treatment with algal based membrane bioreactor for the future: Removing emerging containments
Castrogiovanni et al. Innovative encapsulated self-forming dynamic bio-membrane bioreactor (ESFDMBR) for efficient wastewater treatment and fouling control
Zhou et al. Effects of sulfate on activated sludge characteristics and membrane fouling in membrane bioreactor treating penicillin wastewater
Macedo et al. The use and performance of nanofiltration membranes for agro-industrial effluents purification
Flemming et al. Biofouling on membranes—a short review
CN103539265A (en) Compound microorganism bacterium agent sewage cleaning technology
Shabana et al. Pharmaceutical wastewater treatment using free and immobilized Cyanobacteria
KR20100134343A (en) Alage lysing bacteria rhodococcus sp. kbr-5
Nonato et al. Electroflotation treatment system with down-flow granular filtration (Electroflot-filter) for cyanobacteria removal in drinking water
EP3950602B1 (en) Membrane separation method
Hardörfer et al. Bacteriophobic membranes for decreasing biofilm formation in waste water treatment
JP2013052362A (en) Method for reducing membrane clogging

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002757479

Country of ref document: EP

COP Corrected version of pamphlet

Free format text: PAGES 1/2-2/2, DRAWINGS, REPLACED BY A NEW PAGE 1/1; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWP Wipo information: published in national office

Ref document number: 2002757479

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2002757479

Country of ref document: EP